These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 33476184)

  • 21. Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations.
    Armstrong A; Bui C; Fitch K; Sawhney TG; Brown B; Flanders S; Balk M; Deangelis J; Chambers J
    Curr Med Res Opin; 2017 Jun; 33(6):1133-1139. PubMed ID: 28318331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis.
    Schultz NM; Flanders SC; Wilson S; Brown BA; Song Y; Yang H; Lechpammer S; Kassabian V
    Adv Ther; 2018 Oct; 35(10):1639-1655. PubMed ID: 30191463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cost impact of disease progression to metastatic castration-sensitive prostate cancer.
    Trinh QD; Chaves LP; Feng Q; Zhu J; Sandin R; Abbott T
    J Manag Care Spec Pharm; 2022 May; 28(5):544-554. PubMed ID: 35471070
    [No Abstract]   [Full Text] [Related]  

  • 25. A Real-World Evidence Study Using Alberta-Population-Based Data to Describe Treatment Patterns for Metastatic Castration-Sensitive Prostate Cancer Patients (AWARENESS).
    Karim S; Lowther J; Gyulay G; O'Sullivan D; Wallis CJD; Yip SM; Brenner DR; Boyne DJ; Cheung WY
    Curr Oncol; 2023 Sep; 30(9):8149-8158. PubMed ID: 37754506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increasing prevalence of metastatic castration-resistant prostate cancer in a managed care population in the United States.
    Wallace KL; Landsteiner A; Bunner SH; Engel-Nitz NM; Luckenbaugh AN
    Cancer Causes Control; 2021 Dec; 32(12):1365-1374. PubMed ID: 34386852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Earlier use of androgen receptor-axis-targeted drugs may improve overall survival in patients with non-metastatic castration-resistant prostate cancer.
    Mori K; Kimura T; Ito K; Onuma H; Tanaka M; Matsuura T; Kurokawa G; Iwatani K; Inaba Y; Sakanaka K; Sasaki H; Miki J; Shimomura T; Miki K; Egawa S
    Prostate; 2018 Jul; 78(10):766-772. PubMed ID: 29635810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate cancer across four countries in the Middle East: a multi-centre, observational, retrospective and prognostic study.
    El-Karak F; Shamseddine A; Omar A; Haddad I; Abdelgawad M; Naqqash MA; Kaddour MA; Sharaf M; Abdo E
    Ecancermedicalscience; 2024; 18():1695. PubMed ID: 38774566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world use of systemic therapies in men with metastatic castration resistant prostate cancer (mCRPC) in Canada.
    Shayegan B; Wallis CJD; Malone S; Cagiannos I; Hamilton RJ; Ferrario C; Gotto GT; Basappa NS; Morgan SC; Fernandes R; Morash C; Niazi T; Noonan KL; Rendon R; Osborne B; Park-Wyllie L; Chan KFY; Hotte SJ; Saad F
    Urol Oncol; 2022 May; 40(5):192.e1-192.e9. PubMed ID: 35216890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pattern of Clinical Progression Until Metastatic Castration-Resistant Prostate Cancer: An Epidemiological Study from the European Prostate Cancer Registry.
    Verry C; Vincendeau S; Massetti M; Blachier M; Vimont A; Bazil ML; Bernardini P; Pettré S; Timsit MO
    Target Oncol; 2022 Jul; 17(4):441-451. PubMed ID: 35841526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer.
    Mager R; Savko O; Böhm K; Thomas A; Dotzauer R; Borgmann H; Jäger W; Thomas C; Haferkamp A; Höfner T; Tsaur I
    Urol Oncol; 2019 Dec; 37(12):999-1005. PubMed ID: 31377168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient-reported outcome labeling claims and measurement approach for metastatic castration-resistant prostate cancer treatments in the United States and European Union.
    Clark MJ; Harris N; Griebsch I; Kaschinski D; Copley-Merriman C
    Health Qual Life Outcomes; 2014 Jul; 12():104. PubMed ID: 24989428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidemiology of metastatic castration-resistant prostate cancer: A first estimate of incidence and prevalence using the French nationwide healthcare database.
    Thurin NH; Rouyer M; Gross-Goupil M; Rebillard X; Soulié M; Haaser T; Roumiguié M; Le Moulec S; Capone C; Pierrès M; Lamarque S; Jové J; Bignon E; Droz-Perroteau C; Moore N; Blin P
    Cancer Epidemiol; 2020 Dec; 69():101833. PubMed ID: 33068878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multidisciplinary real-world management of metastatic castration-sensitive prostate cancer: A French national study (PROFILE study).
    Helissey C; Maillet D; Narciso B; Berdah JF; Ouzaid I; Hilgers W; Fiard G; Dubergé T; Jovenin N; Topart D; Beauval JB; Bergeron M; Roubaud G
    Fr J Urol; 2024 Jul; 34(7-8):102661. PubMed ID: 38823482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world prostate-specific antigen response and progression to castration-resistant prostate cancer among men with metastatic castration-sensitive prostate cancer treated with apalutamide: a multi-institutional study in the Chu-shikoku Japan Urological Consortium.
    Tohi Y; Kato T; Kobayashi K; Daizumoto K; Fukuhara H; Ohira S; Katayama S; Shimizu R; Takamoto A; Nishimura K; Ikeda K; Nagami T; Hayashida Y; Hirama H; Naito H; Tomida R; Sasaki Y; Yamamoto S; Shimizu S; Sugimoto M;
    Jpn J Clin Oncol; 2024 Feb; 54(2):167-174. PubMed ID: 37840362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
    Hansen AR; Tannock IF; Templeton A; Chen E; Evans A; Knox J; Prawira A; Sridhar SS; Tan S; Vera-Badillo F; Wang L; Wouters BG; Joshua AM
    Oncologist; 2019 Sep; 24(9):1188-1194. PubMed ID: 30952818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive genomic profiling of treatment resistant metastatic castrate sensitive prostate cancer reveals high frequency of potential therapeutic targets.
    Kappel C; Jiang DM; Wong B; Zhang T; Selvarajah S; Warner E; Hansen AR; Fallah-Rad N; Sacher AG; Stockley TL; Bedard PL; Sridhar SS
    Clin Genitourin Cancer; 2022 Jun; 20(3):278-284. PubMed ID: 35337750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States.
    Kaye DR; Khilfeh I; Muser E; Morrison L; Kinkead F; Lefebvre P; Pilon D; George D
    J Med Econ; 2024; 27(1):381-391. PubMed ID: 38420699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study.
    Boegemann M; Khaksar S; Bera G; Birtle A; Dopchie C; Dourthe LM; Everaert E; Hatzinger M; Hercher D; Hilgers W; Matus G; Alvarez LG; Antoni L; Lukac M; Pissart G; Robinson P; Elliott T
    BMC Cancer; 2019 Jan; 19(1):60. PubMed ID: 30642291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy, Prognostic Factors, and Safety Profile of Enzalutamide for Non-metastatic and Metastatic Castration-Resistant Prostate Cancer: A Retrospective Single-Center Analysis in Japan.
    Fujiwara M; Yuasa T; Komai Y; Numao N; Yamamoto S; Fukui I; Yonese J
    Target Oncol; 2020 Oct; 15(5):635-643. PubMed ID: 33037973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.